Skip to main content
Fig. 1 | BMC Health Services Research

Fig. 1

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Fig. 1

Outline of the Markov model assessing health outcomes of bedaquiline in high burden countries Source: adapted from [9] CE: cost-effectiveness; MDR-TB: multidrug-resistant tuberculosis; XDR-TB: extensively drug-resistant tuberculosis. Note: MDR-TB population includes patients with MDR-TB as well as XDR-TB patients; transitions to the death state are possible from every state, but not shown on the diagram for clarity

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us